BioVersys clears China Phase 1 hurdle for BV100, advancing global pneumonia trial

BioVersys AG ( (CH:BIOV) ) has provided an announcement.

BioVersys has completed a mandatory Phase 1 trial of its lead candidate BV100 in healthy Chinese volunteers, reporting that the intravenous rifabutin formulation was generally safe and well tolerated. The study’s completion enables the company to begin adding Chinese hospitals to its global Phase 3 RIV‑TARGET trial, a key step toward accessing one of the world’s highest-burden markets for carbapenem-resistant Acinetobacter infections.

The RIV‑TARGET registration study, which has already reached its first patient, first visit milestone, is expected to enrol about 300 critically ill patients with hospital- or ventilator-associated pneumonia across roughly 100 sites in 15 countries, with top-line data anticipated within two years. In parallel, BioVersys has launched the open-label Phase 2b RIV‑CARE trial in South-East Asia to compare BV100 with best available therapy in high-resistance settings, aiming to generate real-world evidence that could support differentiation, adoption and eventual commercialization of the drug in regions hardest hit by antimicrobial resistance.

BioVersys frames the BV100 program against an escalating global threat from carbapenem-resistant Acinetobacter baumannii, which it estimates causes over one million severe pneumonia and bloodstream infections annually in China alone, with mortality rates up to 50%. BV100, granted QIDP designation by the U.S. FDA for several critical indications, could strengthen the company’s position in the anti-infectives market by offering a novel mechanism to target Gram-negative pathogens and by securing potential priority review and extended market exclusivity if approved.

The most recent analyst rating on (CH:BIOV) stock is a Buy with a CHF40.00 price target. To see the full list of analyst forecasts on BioVersys AG stock, see the CH:BIOV Stock Forecast page.

More about BioVersys AG

BioVersys AG (SIX: BIOV) is a Basel-based, clinical-stage biopharmaceutical company developing novel antibacterial therapies for life-threatening infections caused by multi-drug resistant bacteria. Its pipeline is built on internal TRIC and Ansamycin Chemistry platforms, with lead programs targeting nosocomial Acinetobacter baumannii infections (BV100, now in Phase 3) and tuberculosis (alpibectir, in Phase 2 with GSK and academic partners).

Average Trading Volume: 3,576

Technical Sentiment Signal: Buy

Current Market Cap: CHF164.3M

Learn more about BIOV stock on TipRanks’ Stock Analysis page.